Sandy Fang, M.D., is a colorectal surgeon who joined us from Johns Hopkins University where she was the Director of the High-Resolution Anoscopy Clinic, Surgical Director for the Anal Cancer Center of Excellence, and the Director of Surgery Apprenticeship Program. Dr. Fang is a high-volume robotics and minimally invasive colorectal surgeon, who specializes in complex abdominal operations to treat colorectal cancer, inflammatory bowel disease, and other benign colorectal disease processes, such as diverticulitis, as well as anorectal disease. She is the is the program director for the High Resolution Anoscopy Clinic, which is a screening tool used to detect anal pre-cancerous lesions or cancer.

She completed her Colon and Rectal Surgery Fellowship through the Salvati Program at the Robert Wood Johnson Medical School and her surgical residency at the University of Iowa. 

After completion of colon and rectal surgery fellowship, Dr. Fang practiced colorectal surgery at The Johns Hopkins Hospital for 9 years.  During her time at Johns Hopkins, she established herself as a robotic surgeon and has become internationally known for her clinical and research programs in anal cancer, innovative surgical techniques, clinical trials, surgical outcomes, and quality improvement.  She is Co-Director of the International Consortium for Anal Cancer Screening.  

Dr. Fang has won multiple teaching awards in general surgery residency and as an attending colorectal surgeon.  In 2016, Dr. Fang was inducted into The Distinguished Teaching Society of The Johns Hopkins University School of Medicine.

Jonathan Brody, Ph.D., is the Vice Chair of Research for the Dept. of Surgery and is the Assoc. Director of the Brenden-Colson Pancreatic Center for Patient Care. He was a member and co-leader of the GI Cancer Program at the Sidney Kimmel Cancer Center (Thomas Jefferson University). Dr. Brody received his Ph.D. from The Johns Hopkins University School of Medicine, and his thesis specialized in studying the molecular aspects of cancer and cancer genetics. He patented, with Dr. Scott Kern, novel buffers for DNA identification (DNA electrophoresis buffer), that have changed the format of this molecular biology technique used to detect DNA. He was elected Chair of the Cancer Research Program (PRCRP), Department of Defense council and serves on many international study sections, including currently being the Chair of the Tumor Biology and Genomics study section for the American Cancer Society and a permanent member of the Cancer Prevention Study Section NCI study section panel. He has published over 135 peer review publications in many top tier scientific and cancer journals. Additionally, he was an American Cancer Society Research Scholar, is NIH (NCI, R01) funded, and won the American Association of Cancer Research, Pancreatic Cancer Career Development Award in 2010.  His lab focuses on many molecular aspects of pancreatic cancer, including developing ways to target a novel pro-survival network in pancreatic cancer cells and optimizing current targeted therapies used in the clinic (i.e., an interest in personalizing therapy for pancreatic cancer patients, PanCAN, RAN grant PI).  Specifically, his lab is focused on an RNA binding protein, HuR, that is a involved in regulating a pro-survival network in various microenvironment settings involved with pancreatic cancer and targeting the DNA repair pathway (i.e., BRCAness) in pancreatic cancer.